Fulcrum Therapeutics Inc [FULC] stock prices are up 3.99% to $11.74 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The FULC shares have gain 21.66% over the last week, with a monthly amount glided 27.33%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on July 29, 2025, and elevated its price target to $12. On May 23, 2025, upgrade upgraded it’s rating to Outperform but maintained its price target of $12 on the stock. Cantor Fitzgerald upgraded its rating to an Overweight but stick to its price target of $10 on May 15, 2025. H.C. Wainwright downgraded its rating to a Neutral and reduced its price target to $4 on September 13, 2024. Stifel downgraded its rating to Hold for this stock on September 12, 2024. In a note dated September 12, 2024, RBC Capital Mkts downgraded an Sector Perform rating on this stock and revised its target price from $15 to $4.
The stock price of Fulcrum Therapeutics Inc [FULC] has been fluctuating between $2.32 and $12.19 over the past year. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. Fulcrum Therapeutics Inc [NASDAQ: FULC] shares were valued at $11.74 at the most recent close of the market. An investor can expect a potential return of 44.8% based on the average FULC price forecast.
Analyzing the FULC fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.32 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.41 points at the first support level, and at 11.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.06, and for the 2nd resistance point, it is at 12.38.
Ratios To Look Out For
It’s worth pointing out that Fulcrum Therapeutics Inc [NASDAQ:FULC]’s Current Ratio is 17.70. Further, the Quick Ratio stands at 17.70, while the Cash Ratio is 4.05.
Transactions by insiders
Recent insider trading involved Gould Robert J, Director, that happened on Nov 19 ’25 when 15000.0 shares were sold. Director, ROBERT J GOULD completed a deal on Nov 19 ’25 to buy 45000.0 shares. Meanwhile, Principal Accounting Officer Tourangeau Greg sold 498.0 shares on May 08 ’25.
